Authors




Matthew T. Campbell, MD, MS

Latest:

Scratching the Surface in Managing Advanced RCC

Matthew T. Campbell, MD, MS, discusses CAR T-cell therapy and immunotherapy advances in renal cell carcinoma.



Murali Janakiram, MD, MS

Latest:

CARTITUDE-4 Study: Cilta-Cel vs Standard of Care for Lenalidomide-Refractory Multiple Myeloma

Panelists review the CARTITUDE-4 study results highlighting the efficacy of cilta-cel in lenalidomide-refractory multiple myeloma, addressing implementation challenges and patient preferences in varying relapse scenarios.






Karen H. Lu, MD

Latest:

Karen H. Lu, MD, on Next Steps in Evaluating Genetic Testing in Underrepresented Minorities

The MD Anderson Cancer Center expert discussed further research in delivering online accessible genetic testing.


Eileen O’Reilly, MD

Latest:

Treatment Paradigm for Early-Stage Pancreatic Cancer Diagnosis

With Eileen O’Reilly, MD, the Oncology Brothers discuss the current treatment paradigm for early-stage pancreatic cancer, focusing on diagnostic strategies, surgical options, and adjuvant therapies to improve patient outcomes.


Mariana Licano-Zubiate, MD

Latest:

Metastatic Renal Cell Carcinoma With Sarcomatoid Features

In this installement of Clinical Quandaries, Abigail Mateos-Soria, MD, and colleagues present a case of an 38-year-old woman who has a 3-month history of fatigue, dyspnea, significant weight loss, and severe left flank pain.





Jeffrey M. Ryckman, MD

Latest:

Adverse Effects Associated with SBRT in Patients With HCC

The panel discusses adverse effects associated with stereotactic body radiation therapy, and the Oncology Brothers provide a recap of the entire discussion.



Anjali Hari, MD

Latest:

Anjali Hari, MD, Highlights the Rationale for Assessing HIPEC in Frail and Non-Frail Ovarian Cancer

Anjali Y. Hari, MD, speaks to the rationale for examining hyperthermic intraperitoneal chemotherapy in a population of frail and non-frail patients with ovarian cancer.


Sunraj Tharu, BSc

Latest:

Danazol for the Treatment of Myelodysplastic Syndromes: A Systematic Review

Danazol was reviewed as an effective treatment option for patients with myelodyspplastic syndromes, according to a recently published article by Sangam Shah, MBBS, et al.


Samuel Rosner, MD

Latest:

Patient Case Presentation: A 69-Year-Old With Newly Diagnosed EGFR-Mutant mNSCLC and Symptomatic Brain Metastases

Panelists discuss how a 69-year-old woman with newly diagnosed EGFR-mutant mNSCLC and symptomatic brain metastases requires immediate multidisciplinary care including steroids, radiation oncology consultation, and potential hospitalization, with treatment approach favoring stereotactic radiosurgery for dominant lesions followed by combination therapy like FLAURA2, while emphasizing that asymptomatic patients might allow for initial tyrosine kinase inhibitor treatment with close monitoring before considering radiation to potentially reduce treatment field and minimize long-term neurotoxicity.



Linie Chi, NP

Latest:

Renal Cell Carcinoma: Practical Advice for Patients, Caregivers, and Physicians

Practical advice on the management of renal cell carcinoma provided for healthcare professionals, patients, and caregivers alike.



Samia Asif, MBBS

Latest:

Unusual Clinical Presentation of Clear Cell Sarcoma in a Young Woman

A young woman presents with painless lumps to the emergency department and is later diagnosed with clear cell carcinoma.


Bryan Lewis

Latest:

Emphasizing The Need to Sustain Kidney Cancer Research Funding at KCRS 2025

The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.


Alison Conlin, MD

Latest:

Metastatic Triple-Negative Breast Cancer: Unmet Needs and Future Directions in Care

Expert oncologists highlight remaining unmet needs in the setting of metastatic triple-negative breast cancer and look toward future evolutions in care.


Chengping Hu, MD

Latest:

Profilin 1 Protein and Its Implications for Cancers

Profilin 1, or PFN1, is a key actin-binding protein that is involved in various cellular activities, such as cell motility, survival, and membrane trafficking. By summarizing the functions of PFN1 in cancer, investigators hope to better understand the mechanisms of PFN1 in cancer progression.



Irina Melnichenko, MD

Latest:

How to Treat Metastatic Malignant Triton Tumor in an Adolescent

A systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.